{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:57:30Z","timestamp":1786982250352,"version":"build-2736575974"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2018,11,21]],"date-time":"2018-11-21T00:00:00Z","timestamp":1542758400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004622","name":"KWF Kankerbestrijding","doi-asserted-by":"publisher","award":["2009-4402"],"award-info":[{"award-number":["2009-4402"]}],"id":[{"id":"10.13039\/501100004622","id-type":"DOI","asserted-by":"publisher"}]},{"name":"H2020 European Research Council advanced grant PATHFINDER","award":["269019"],"award-info":[{"award-number":["269019"]}]},{"DOI":"10.13039\/501100003246","name":"Nederlandse Organisatie voor Wetenschappelijk Onderzoek","doi-asserted-by":"crossref","award":["Spinoza grant"],"award-info":[{"award-number":["Spinoza grant"]}],"id":[{"id":"10.13039\/501100003246","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100003246","name":"Nederlandse Organisatie voor Wetenschappelijk Onderzoek","doi-asserted-by":"crossref","award":["Vici grant (918.14.655)"],"award-info":[{"award-number":["Vici grant (918.14.655)"]}],"id":[{"id":"10.13039\/501100003246","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Transl Oncol"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1007\/s12094-018-1987-0","type":"journal-article","created":{"date-parts":[[2018,11,21]],"date-time":"2018-11-21T01:48:55Z","timestamp":1542764935000},"page":"774-780","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Health-related quality of life analysis in stage III melanoma patients treated with adjuvant dendritic cell therapy"],"prefix":"10.1007","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9395-4214","authenticated-orcid":false,"given":"M.","family":"Bloemendal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7780-1250","authenticated-orcid":false,"given":"M. J. A.","family":"Rietveld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W. W.","family":"van Willigen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W. R.","family":"Gerritsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2366-9212","authenticated-orcid":false,"given":"C. G.","family":"Figdor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3608-4184","authenticated-orcid":false,"given":"J. J.","family":"Bonenkamp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3336-4164","authenticated-orcid":false,"given":"H.","family":"Westdorp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4201-3507","authenticated-orcid":false,"given":"S.","family":"Boudewijns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5446-755X","authenticated-orcid":false,"given":"R. H. T.","family":"Koornstra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4773-6176","authenticated-orcid":false,"given":"E. M. M.","family":"Adang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0156-8365","authenticated-orcid":false,"given":"G.","family":"Schreibelt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8209-487X","authenticated-orcid":false,"given":"P. B.","family":"Ottevanger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8653-4040","authenticated-orcid":false,"given":"I. J. M.","family":"de Vries","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4165-2040","authenticated-orcid":false,"given":"K. F.","family":"Bol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,11,21]]},"reference":[{"issue":"2","key":"1987_CR1","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1002\/ijc.27616","volume":"132","author":"F Erdmann","year":"2013","unstructured":"Erdmann F, Lortet-Tieulent J, Schuz J, Zeeb H, Greinert R, Breitbart EW, et al. International trends in the incidence of malignant melanoma 1953\u20132008\u2014are recent generations at higher or lower risk? Int J Cancer. 2013;132(2):385\u2013400. \n                    https:\/\/doi.org\/10.1002\/ijc.27616\n                    \n                  .","journal-title":"Int J Cancer"},{"key":"1987_CR2","unstructured":"Estimated number of incident cases, both sexes, melanoma of skin, worldwide. Cancer Today International Agency for Research on Cancer. \n                    https:\/\/gco.iarc.fr\n                    \n                   (2012). Accessed 9 Jan 2018."},{"issue":"23","key":"1987_CR3","doi-asserted-by":"publisher","first-page":"2211","DOI":"10.1056\/NEJMoa1613210","volume":"376","author":"MB Faries","year":"2017","unstructured":"Faries MB, Thompson JF, Cochran AJ, Andtbacka RH, Mozzillo N, Zager JS, et al. Completion dissection or observation for sentinel-node metastasis in melanoma. N Engl J Med. 2017;376(23):2211\u201322. \n                    https:\/\/doi.org\/10.1056\/NEJMoa1613210\n                    \n                  .","journal-title":"N Engl J Med"},{"issue":"36","key":"1987_CR4","doi-asserted-by":"publisher","first-page":"6199","DOI":"10.1200\/JCO.2009.23.4799","volume":"27","author":"CM Balch","year":"2009","unstructured":"Balch CM, Gershenwald JE, Soong S-J, Thompson JF, Atkins MB, Byrd DR, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol. 2009;27(36):6199\u2013206.","journal-title":"J Clin Oncol"},{"issue":"9","key":"1987_CR5","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1016\/S1470-2045(15)00187-4","volume":"16","author":"MA Henderson","year":"2015","unstructured":"Henderson MA, Burmeister BH, Ainslie J, Fisher R, Di Iulio J, Smithers BM, et al. Adjuvant lymph-node field radiotherapy versus observation only in patients with melanoma at high risk of further lymph-node field relapse after lymphadenectomy (ANZMTG 01.02\/TROG 02.01): 6-year follow-up of a phase 3, randomised controlled trial. Lancet Oncol. 2015;16(9):1049\u201360. \n                    https:\/\/doi.org\/10.1016\/S1470-2045(15)00187-4\n                    \n                  .","journal-title":"Lancet Oncol"},{"key":"1987_CR6","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1611299","author":"AM Eggermont","year":"2016","unstructured":"Eggermont AM, Chiarion-Sileni V, Grob JJ, Dummer R, Wolchok JD, Schmidt H, et al. Prolonged survival in stage III melanoma with ipilimumab adjuvant therapy. N Engl J Med. 2016. \n                    https:\/\/doi.org\/10.1056\/nejmoa1611299\n                    \n                  .","journal-title":"N Engl J Med"},{"key":"1987_CR7","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1708539","author":"GV Long","year":"2017","unstructured":"Long GV, Hauschild A, Santinami M, Atkinson V, Mandala M, Chiarion-Sileni V, et al. Adjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanoma. N Engl J Med. 2017. \n                    https:\/\/doi.org\/10.1056\/nejmoa1708539\n                    \n                  .","journal-title":"N Engl J Med"},{"key":"1987_CR8","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1709030","author":"J Weber","year":"2017","unstructured":"Weber J, Mandala M, Del Vecchio M, Gogas HJ, Arance AM, Cowey CL, et al. Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma. N Engl J Med. 2017. \n                    https:\/\/doi.org\/10.1056\/nejmoa1709030\n                    \n                  .","journal-title":"N Engl J Med"},{"key":"1987_CR9","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1802357","author":"AMM Eggermont","year":"2018","unstructured":"Eggermont AMM, Blank CU, Mandala M, Long GV, Atkinson V, Dalle S, et al. Adjuvant pembrolizumab versus placebo in resected stage III melanoma. N Engl J Med. 2018. \n                    https:\/\/doi.org\/10.1056\/nejmoa1802357\n                    \n                  .","journal-title":"N Engl J Med"},{"issue":"18 Pt 1","key":"1987_CR10","doi-asserted-by":"publisher","first-page":"5256","DOI":"10.1158\/1078-0432.CCR-07-0892","volume":"13","author":"TF Gajewski","year":"2007","unstructured":"Gajewski TF. Failure at the effector phase: immune barriers at the level of the melanoma tumor microenvironment. Clin Cancer Res. 2007;13(18 Pt 1):5256\u201361. \n                    https:\/\/doi.org\/10.1158\/1078-0432.CCR-07-0892\n                    \n                  .","journal-title":"Clin Cancer Res"},{"issue":"15","key":"1987_CR11","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1200\/JCO.2016.71.9393","volume":"35","author":"LE Haydu","year":"2017","unstructured":"Haydu LE, Scolyer RA, Lo S, Quinn MJ, Saw RPM, Shannon KF, et al. Conditional survival: an assessment of the prognosis of patients at time points after initial diagnosis and treatment of locoregional melanoma metastasis. J Clin Oncol. 2017;35(15):1721\u20139. \n                    https:\/\/doi.org\/10.1200\/JCO.2016.71.9393\n                    \n                  .","journal-title":"J Clin Oncol"},{"issue":"7","key":"1987_CR12","doi-asserted-by":"publisher","first-page":"e257","DOI":"10.1016\/S1470-2045(13)70585-0","volume":"15","author":"S Anguille","year":"2014","unstructured":"Anguille S, Smits EL, Lion E, van Tendeloo VF, Berneman ZN. Clinical use of dendritic cells for cancer therapy. Lancet Oncol. 2014;15(7):e257\u201367. \n                    https:\/\/doi.org\/10.1016\/S1470-2045(13)70585-0\n                    \n                  .","journal-title":"Lancet Oncol"},{"issue":"4","key":"1987_CR13","doi-asserted-by":"publisher","first-page":"e18801","DOI":"10.1371\/journal.pone.0018801","volume":"6","author":"A Draube","year":"2011","unstructured":"Draube A, Klein-Gonzalez N, Mattheus S, Brillant C, Hellmich M, Engert A, et al. Dendritic cell based tumor vaccination in prostate and renal cell cancer: a systematic review and meta-analysis. PLoS ONE. 2011;6(4):e18801. \n                    https:\/\/doi.org\/10.1371\/journal.pone.0018801\n                    \n                  .","journal-title":"PLoS ONE"},{"issue":"9","key":"1987_CR14","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1007\/s00262-012-1207-7","volume":"61","author":"N Leonhartsberger","year":"2012","unstructured":"Leonhartsberger N, Ramoner R, Falkensammer C, Rahm A, Gander H, Holtl L, et al. Quality of life during dendritic cell vaccination against metastatic renal cell carcinoma. Cancer Immunol Immunother. 2012;61(9):1407\u201313. \n                    https:\/\/doi.org\/10.1007\/s00262-012-1207-7\n                    \n                  .","journal-title":"Cancer Immunol Immunother"},{"issue":"6","key":"1987_CR15","first-page":"1305","volume":"20","author":"SK Burgdorf","year":"2008","unstructured":"Burgdorf SK, Fischer A, Myschetzky PS, Munksgaard SB, Zocca MB, Claesson MH, et al. Clinical responses in patients with advanced colorectal cancer to a dendritic cell based vaccine. Oncol Rep. 2008;20(6):1305\u201311.","journal-title":"Oncol Rep"},{"issue":"11","key":"1987_CR16","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1007\/s00262-015-1746-9","volume":"64","author":"AE Skold","year":"2015","unstructured":"Skold AE, van Beek JJ, Sittig SP, Bakdash G, Tel J, Schreibelt G, et al. Protamine-stabilized RNA as an ex vivo stimulant of primary human dendritic cell subsets. Cancer Immunol Immunother. 2015;64(11):1461\u201373. \n                    https:\/\/doi.org\/10.1007\/s00262-015-1746-9\n                    \n                  .","journal-title":"Cancer Immunol Immunother"},{"issue":"5","key":"1987_CR17","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1007\/BF00449426","volume":"2","author":"HE Niezgoda","year":"1993","unstructured":"Niezgoda HE, Pater JL. A validation-study of the domains of the core eortc quality-of-life questionnaire. Qual Life Res. 1993;2(5):319\u201325. \n                    https:\/\/doi.org\/10.1007\/Bf00449426\n                    \n                  .","journal-title":"Qual Life Res"},{"issue":"11","key":"1987_CR18","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1016\/S0959-8049(01)00127-7","volume":"37","author":"PM Fayers","year":"2001","unstructured":"Fayers PM. Interpreting quality of life data: population-based reference data for the EORTC QLQ-C30. Eur J Cancer. 2001;37(11):1331\u20134. \n                    https:\/\/doi.org\/10.1016\/S0959-8049(01)00127-7\n                    \n                  .","journal-title":"Eur J Cancer"},{"issue":"1","key":"1987_CR19","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1200\/JCO.1998.16.1.139","volume":"16","author":"D Osoba","year":"1998","unstructured":"Osoba D, Rodrigues G, Myles J, Zee B, Pater J. Interpreting the significance of changes in health-related quality-of-life scores. J Clin Oncol. 1998;16(1):139\u201344.","journal-title":"J Clin Oncol"},{"issue":"6","key":"1987_CR20","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1007\/BF00439229","volume":"5","author":"MT King","year":"1996","unstructured":"King MT. The interpretation of scores from the EORTC quality of life questionnaire QLQ-C30. Qual Life Res. 1996;5(6):555\u201367. \n                    https:\/\/doi.org\/10.1007\/Bf00439229\n                    \n                  .","journal-title":"Qual Life Res"},{"key":"1987_CR21","volume-title":"EORTC QLQ-C30 scoring manual","author":"PM Fayers","year":"2001","unstructured":"Fayers PM, Aaronson NK, Bjordal K, Groenvold M, Curran D, Bottomley A. EORTC QLQ-C30 scoring manual. 3rd ed. Brussels: The EORTC Quality of Life Group; 2001.","edition":"3"},{"issue":"3","key":"1987_CR22","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/S1470-2045(17)30015-3","volume":"18","author":"C Coens","year":"2017","unstructured":"Coens C, Suciu S, Chiarion-Sileni V, Grob JJ, Dummer R, Wolchok JD, et al. Health-related quality of life with adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): secondary outcomes of a multinational, randomised, double-blind, phase 3 trial. Lancet Oncol. 2017;18(3):393\u2013403. \n                    https:\/\/doi.org\/10.1016\/S1470-2045(17)30015-3\n                    \n                  .","journal-title":"Lancet Oncol"},{"issue":"18","key":"1987_CR23","doi-asserted-by":"publisher","first-page":"2916","DOI":"10.1200\/JCO.2008.20.2069","volume":"27","author":"A Bottomley","year":"2009","unstructured":"Bottomley A, Coens C, Suciu S, Santinami M, Kruit W, Testori A, et al. Adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma: a phase III randomized controlled trial of health-related quality of life and symptoms by the European Organisation for Research and Treatment of Cancer Melanoma Group. J Clin Oncol. 2009;27(18):2916\u201323. \n                    https:\/\/doi.org\/10.1200\/JCO.2008.20.2069\n                    \n                  .","journal-title":"J Clin Oncol"},{"issue":"6","key":"1987_CR24","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1093\/annonc\/mdn001","volume":"19","author":"C Garbe","year":"2008","unstructured":"Garbe C, Radny P, Linse R, Dummer R, Gutzmer R, Ulrich J, et al. Adjuvant low-dose interferon {alpha}2a with or without dacarbazine compared with surgery alone: a prospective-randomized phase III DeCOG trial in melanoma patients with regional lymph node metastasis. Ann Oncol. 2008;19(6):1195\u2013201. \n                    https:\/\/doi.org\/10.1093\/annonc\/mdn001\n                    \n                  .","journal-title":"Ann Oncol"},{"issue":"7","key":"1987_CR25","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1038\/nrclinonc.2017.60","volume":"14","author":"P Lorigan","year":"2017","unstructured":"Lorigan P, Green AC. Immunotherapy: does adjuvant ipilimumab have little adverse effect on quality of life? Nat Rev Clin Oncol. 2017;14(7):395\u20136. \n                    https:\/\/doi.org\/10.1038\/nrclinonc.2017.60\n                    \n                  .","journal-title":"Nat Rev Clin Oncol"},{"issue":"3","key":"1987_CR26","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/S0163-8343(00)00076-1","volume":"22","author":"JR Peteet","year":"2000","unstructured":"Peteet JR. Cancer and the meaning of work. Gen Hosp Psychiatry. 2000;22(3):200\u20135.","journal-title":"Gen Hosp Psychiatry"},{"issue":"34","key":"1987_CR27","doi-asserted-by":"publisher","first-page":"4077","DOI":"10.1200\/JCO.2014.59.6932","volume":"33","author":"P Mohr","year":"2015","unstructured":"Mohr P, Hauschild A, Trefzer U, Enk A, Tilgen W, Loquai C, et al. Intermittent high-dose intravenous interferon alfa-2b for adjuvant treatment of stage III melanoma: final analysis of a randomized phase III dermatologic cooperative oncology group trial. J Clin Oncol. 2015;33(34):4077\u201384. \n                    https:\/\/doi.org\/10.1200\/JCO.2014.59.6932\n                    \n                  .","journal-title":"J Clin Oncol"}],"container-title":["Clinical and Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-018-1987-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12094-018-1987-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-018-1987-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,20]],"date-time":"2019-11-20T19:26:48Z","timestamp":1574278008000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12094-018-1987-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,21]]},"references-count":27,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019,6]]}},"alternative-id":["1987"],"URL":"https:\/\/doi.org\/10.1007\/s12094-018-1987-0","relation":{},"ISSN":["1699-048X","1699-3055"],"issn-type":[{"value":"1699-048X","type":"print"},{"value":"1699-3055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11,21]]},"assertion":[{"value":"21 September 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 November 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 November 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}